Astellas Pharma Inc. announced that it launched Kiklin Granules 86.2% (generic name: bixalomer, Kiklin Granules), an additional formulation of Kiklin Capsules 250 mg (Kiklin Capsules), for the indication of treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) in Japan today. Astellas expects to further contribute to hyperphosphatemia treatment by introducing Kiklin Granules which can further improve the compliance with its more convenient dosing option into Japanese market. Hyperphosphatemia occurs in patients whose renal function is decreased, since phosphorus is not sufficiently excreted into urine via the kidneys and consequently accumulates in the body. With continuous high blood phosphorus concentration, the risk of renal osteodystrophy characterized by a high tendency of bone pain and bone fracture is known to be increased. Additionally, high blood phosphorus concentration is associated with increased coronary artery calcification and subsequent cardiovascular events. Therefore, it is considered extremely important to maintain the serum phosphorus concentration at an appropriate level in CKD patients. Bixalomer is amine-functional polymers which decrease the serum phosphorus concentration by binding to phosphate in the gastrointestinal tract, thus inhibiting absorption of phosphate into the human body.